Belgium
· Delayed Price · Currency is EUR Hyloris Pharmaceuticals Statistics
Total Valuation
EBR:HYL has a market cap or net worth of EUR 168.00 million. The enterprise value is 145.67 million.
| Market Cap | 168.00M |
| Enterprise Value | 145.67M |
Important Dates
The last earnings date was Thursday, March 20, 2025.
| Earnings Date | Mar 20, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
EBR:HYL has 28.00 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 28.00M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 56.83% |
| Owned by Institutions (%) | 0.08% |
| Float | 12.09M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 5.94 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -22.97 |
| EV / Sales | 14.51 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -21.64 |
Financial Position
The company has a current ratio of 4.15, with a Debt / Equity ratio of 0.06.
| Current Ratio | 4.15 |
| Quick Ratio | 4.12 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.27 |
| Interest Coverage | -16.08 |
Financial Efficiency
Return on equity (ROE) is -17.81% and return on invested capital (ROIC) is -10.16%.
| Return on Equity (ROE) | -17.81% |
| Return on Assets (ROA) | -8.53% |
| Return on Invested Capital (ROIC) | -10.16% |
| Return on Capital Employed (ROCE) | -17.78% |
| Revenue Per Employee | 204,939 |
| Profits Per Employee | -129,429 |
| Employee Count | 49 |
| Asset Turnover | 0.23 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -46.55% in the last 52 weeks. The beta is 0.33, so EBR:HYL's price volatility has been lower than the market average.
| Beta (5Y) | 0.33 |
| 52-Week Price Change | -46.55% |
| 50-Day Moving Average | 5.59 |
| 200-Day Moving Average | 6.59 |
| Relative Strength Index (RSI) | 52.40 |
| Average Volume (20 Days) | 18,756 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, EBR:HYL had revenue of EUR 10.04 million and -6.34 million in losses.
| Revenue | 10.04M |
| Gross Profit | 9.82M |
| Operating Income | -6.08M |
| Pretax Income | -6.34M |
| Net Income | -6.34M |
| EBITDA | -4.85M |
| EBIT | -6.08M |
| Earnings Per Share (EPS) | n/a |
Balance Sheet
The company has 24.15 million in cash and 1.82 million in debt, giving a net cash position of 22.34 million or 0.80 per share.
| Cash & Cash Equivalents | 24.15M |
| Total Debt | 1.82M |
| Net Cash | 22.34M |
| Net Cash Per Share | 0.80 |
| Equity (Book Value) | 32.14M |
| Book Value Per Share | n/a |
| Working Capital | 22.55M |
Cash Flow
In the last 12 months, operating cash flow was -6.70 million and capital expenditures -29,000, giving a free cash flow of -6.73 million.
| Operating Cash Flow | -6.70M |
| Capital Expenditures | -29,000 |
| Free Cash Flow | -6.73M |
| FCF Per Share | -0.24 |
Margins
Gross margin is 97.74%, with operating and profit margins of -60.52% and -63.15%.
| Gross Margin | 97.74% |
| Operating Margin | -60.52% |
| Pretax Margin | -63.15% |
| Profit Margin | -63.15% |
| EBITDA Margin | -48.28% |
| EBIT Margin | -60.52% |
| FCF Margin | n/a |
Dividends & Yields
EBR:HYL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -3.77% |
| FCF Yield | -4.01% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
EBR:HYL has an Altman Z-Score of 14.7.
| Altman Z-Score | 14.7 |
| Piotroski F-Score | n/a |